Dr. Gupta Discusses Adjuvant Immunotherapy in Kidney Cancer

Shilpa Gupta, MD
Published: Monday, Aug 07, 2017



Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses adjuvant immunotherapy in kidney cancer.

There is a lot of interest in adjuvant therapy in kidney cancer, Gupta says. Trials with immunotherapy are being compared with placebo, but Gupta says that these agents should probably be compared with sunitinib (Sutent), if it gains FDA approval.

Additionally, Gupta says that patients with non-clear cell kidney cancer should be included in these adjuvant trials as well.
 


Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses adjuvant immunotherapy in kidney cancer.

There is a lot of interest in adjuvant therapy in kidney cancer, Gupta says. Trials with immunotherapy are being compared with placebo, but Gupta says that these agents should probably be compared with sunitinib (Sutent), if it gains FDA approval.

Additionally, Gupta says that patients with non-clear cell kidney cancer should be included in these adjuvant trials as well.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x